NPS Pharmaceuticals price target raised to $28 from $20 at Needham Needham raised its target on NPS after the company reported higher than expected Q2 sales of Gattex. The firm believes that the Gattex launch is progressing well, and it reiterates a Buy rating on the shares.
News For NPSP From The Last 14 Days
Check below for free stories on NPSP the last two weeks.
NPS Pharmaceuticals weakness attributed to comments on Natpara NPS Pharmaceuticals management said at a conference hosted by Deutshce Bank that it does not know if an FDA panel will be need for Natpara, according to Bloomberg. The company said it doesn't expect a priority review for Natpara, the news service added. Shares of NPS have fallen to session lows, down 7.7% to $24.04.
Deutsche Bank to host a conference BioFest is being held in Boston on December 2-3 with webcasted company presentations to begin on December 3 at 7:50 am; not all company presentations may be webcasted. Webcast Link